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Abstract
Background. End-stage renal disease (ESRD) results in
increased susceptibility to infections, impaired response
to vaccination and diffuse B-cell lymphopenia. However,
the precise nature and mechanism of ESRD-induced B-cell
lymphopenia remains unclear. Therefore, we studied the
distribution of major B-cell subsets, B-cell growth, differ-
entiation and survival factors, IL-7 and BAFF, and their
receptors in 21 haemodialysis patients and 21 controls.
Methods. Innate B1 cells (CD19+,C D 5 +), conventional
B2 cells (CD19+,C D 5 −), newly formed transitional B
cells (CD19+,C D 1 0 +,C D 2 7 −), na¨ ıve B cells (CD19+,
CD27−) and memory B cells (CD19+,C D 2 7 +) and
BAFF receptor were quantified by flow cytometry. Plasma
IL-7, BAFF, IL-6, TNF-α and IL-10 were measured by
ELISA.
Results. The ESRD group exhibited significant reductions
of all B-cell subpopulations except for transitional B cells
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that were less severely affected. No significant difference
was found in B-cell apoptosis between the ESRD and con-
trol groups. Moreover, plasma IL-7 and BAFF levels were
elevated in ESRD patients, therefore excluding their de-
ficiencies as a possible culprit. However, BAFF receptor
expression was significantly reduced in transitional but not
mature B cells in the ESRD group. Interestingly, B-cell
activation with the TLR9 agonist resulted in significantly
greater production of IL-6 and TNF alpha but not IL-10 in
the ESRD group.
Conclusions. Thus, despite elevation of B-cell growth, dif-
ferentiation and survival factors, ESRD patients exhibited
diffuse reduction of B-cell subpopulations. This was asso-
ciated with the down-regulation of BAFF receptor in tran-
sitional B cells. The latter can, in part, contribute to B-cell
lymphopenia by promoting resistance to the biological ac-
tions of BAFF that is a potent B-cell differentiation and
survival factor.
Keywords: infection; immune system; inflammation; vaccination;
antibody production
Introduction
While bacterial infections have diminished as a cause of
death in the general population, they remain the second
most common cause of death in the end-stage renal disease
(ESRD) population [1–3]. This is thought to be largely due
to the impaired host immune response in uraemia [1,4,5].
Reported immunological abnormalities in ESRD patients
include decreased granulocyte and monocyte/macrophage
phagocytic function [4,6,7], defective antigen presentation
by monocyte/macrophages [4,8,9], reduced antibody pro-
duction by B lymphocytes [4,10,11] and impaired T-cell-
mediated immunity [4,12,13]. The exact mechanisms re-
sponsible for these derangements are not fully understood.
Werecentlyreportedthatna¨ ıveandcentralmemory,butnot
effector memory, CD 4+ and CD8+ T cells are depleted in
ESRD patients [14].
B lymphocytes (CD19+) are precursors of plasma cells
that are responsible for antibody production. Upon con-
tact with the antigen, na¨ ıve B cells undergo clonal ex-
pansion/differentiation that leads to formation of mem-
ory B cells and antibody-secreting plasma cells. Periph-
eral blood B cells (CD19+) are comprised of distinct phe-
notypical/functional subpopulations including innate B1
cells (CD19+,C D 5 +), conventional B2 cells (CD19+,
CD5−), newly formed transitional B cells (CD19+,
CD10+,CD27−), na¨ ıve B cells (CD19+,C D 2 7 −) and
memory B cells (CD19+,C D 2 7 +).
Earlier studies have documented a significant reduction
in the peripheral blood total B-cell count in ESRD. How-
ever, little is known about the effect of ESRD on B-cell
subpopulations. To address the phenotypic changes in the
B cells, we studied distribution of the major B-cell subsets
in peripheral blood of 21 haemodialysis-dependent ESRD
patients and 21 control individuals.
Materials and methods
Patients
The study protocol was approved by Human Subjects Institutional Re-
view Board of the University of California Irvine and completed with
the assistance of the University of California General Clinical Research
Center.
Twenty-one stable patients with ESRD maintained on haemodialysis
for an average of 38.5 months (3–113 months) were recruited for the
study. Individuals with evidence of acute or chronic infection, acute in-
tercurrent illnesses and those receiving immunosuppressive drugs were
excluded. Medical history, systolic and diastolic blood pressures, body
weight, routine monthly laboratory data and medications were recorded.
Haemodialysis therapy was performed thrice weekly using cellulose triac-
etate dialysers.
A group of 21 normal age-matched control subjects served as controls.
Control subjects exhibiting acute or chronic infection, acute intercurrent
illnesses, chronic illnesses such as hypertension, diabetes, malignancy,
psychiatric disorders or those requiring chronic medications were ex-
cluded. All participants provided informed consent prior to enrolment in
the study. Blood haemoglobin, total leukocyte and differential counts and
plasma biochemical measurements were obtained using standard labora-
tory methods.
Blood collection
In all ESRD patients, whole blood was collected from the vascular access
prior to the initiation of dialysis. The blood samples were obtained by a
syringe,applyinggentleaspirationtominimizeshearstress.Bloodsamples
form the control individuals were collected from a peripheral vein in the
same manner.
Immunostaining
B-lymphocyte subsets were analysed by triple-colour flow cytometry us-
ing PerCP-conjugated anti-CD19 monoclonal antibodies (mAb), FITC-
conjugated anti-CD 27 mAb and PE-conjugated anti-CD5, anti-CD10 or
isotypecontrolmAb.Antibodiesandisotypecontrolswerepurchasedfrom
B.D. Biosciences, San Diego, CA, USA. A total of 100 µL of whole blood
was incubated with 10 µL of each of the above antibodies for 15 min at
room temperature in the dark. The cells were then incubated in 2 mL
of the FACS lysing solution (Becton-Dickinson, San Jose, CA, USA) for
15 min to lyse red blood cells. The cells were then washed twice with
phosphate-buffered saline (1X PBS) to remove red blood cell remnants,
and lymphocytes were resuspended, in 0.5 mL of 1% paraformaldehyde,
and used for flow cytometry.
Flow cytometry
Lymphocyte phenotyping was carried out by three-colour analysis using a
FACSort flow cytometer and CellQuest software (Becton-Dickinson, San
Jose, CA, USA). For each sample, data from 10 000 cells were collected
and analysed. Forward and side scatters were used to gate and exclude
cellular debris, and FL3 channels were used to gate CD19+ B cells.
During analysis, an electronic gate was placed on CD19+ B cells. The
associated expression of CD27 versus CD10 and CD5 was then used to
obtain the percentages of cells identifying (CD19+,C D 2 7 +), (CD19+ ,
CD10+), (CD19+,C D 5 +) and subsets of CD 19+ B cells.
Detection of apoptosis
Apoptosis was measured by the Annexin V-FITC binding assay according
tothemanufacturer’sinstructions(BDBiosciences).Annexinstainingwas
performed both in whole blood and isolated lymphocytes. Briefly, 100 µL
of whole blood or isolated peripheral blood mononuclear cells (0.5 ×
106) were stained with 10 µL of PerCP-conjugated anti-CD19 antibody,
washedtwicewith2mLofPBSandRBCwerelysedwiththeFACSlysing
buffer. The cells were washed and resuspended in 100 µL of the Annexin
V-conjugate binding buffer to which 5 µL of FITC-conjugated Annexin
V was added. The mixture was incubated in a dark at room temperature
for 15 min, after which 400 µL of the binding buffer was added and 5000
cellswereacquiredandanalysedbyFACS.FL3channelswereusedtogate
CD19+ B cells and the FL1 channel was used to detect the population of
cells positive for Annexin V-FITC.Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression 207
Table 1. Clinical and biochemical parameters in normal control and
ESRD groups (mean ± SD)
Control ESRD
(n = 21) (n = 21) P-value
Age (years) 47 ± 13 52 ± 16 NS
Gender (male/female) 10/11 11/10
BUN (mg/dL) 13.3 ± 1.02 73.5 ± 25.3 <0.001
Creatinine (mg/dL) 0.85 ± 0.18 10.9 ± 3.3 <0.001
Calcium (mg/dL) 9.1 ± 0.24 8.9 ± 0.6 NS
Phosphorus (mg/dL) 3.2 ± 0.16 5.9 ± 1.8 <0.001
iPTH (pg/mL) 40.0 ± 3.84 334.1 ± 268.3 <0.001
Haemoglobin (g/dL) 14.6 ± 1.1 11.9 ± 1.2 <0.001
Ferritin (ng/mL) 32.63 ± 6.26 309.1 ± 211.3 <0.001
Transferrin saturation (%) 18.66 ± 2.12 24.8 ± 8.0 0.012
Albumin (g/dL) 3.8 ± 0.14 3.8 ± 0.3 NS
Cholesterol (mg/dL) 159.5 ± 5.47 141.4 ± 36.4 0.031
Triglyceride (mg/dL) 100.2 ± 15.5 167.5 ± 140.8 0.052
Kt/V – 1.62 ± 0.74
Measurement of IL-7 and BAFF
Plasma IL-7 and B-cell-activating factor of the TNF family (BAFF) were
measuredbyELISAusingkitspurchasedfromR&Dsystems(Minneapo-
lis,MN).Briefly,96-wellmicrotiterplatespre-coatedwithIL-7andBAFF
antibody were incubated with suitable dilutions of the plasma. Bound cy-
tokines were detected using enzyme-linked detection antibodies. After
washing and addition of substrate and an amplifier, the OD in the wells
was measured at 490 nm, and background values were subtracted. The av-
erageofduplicatemeasurementswastaken.Cytokineconcentrationsinthe
sampleswerederivedfromastandardcurveusingpurifiedIL-7andBAFF.
Measurement of BAFF and IL-7 receptors
Triple colour Flow cytometry was used to assess BAFF and IL7 receptor
expression on B cells. Briefly, whole blood was stained using PE-Cy5-
conjugated anti-CD19, PE-conjugated anti-CD10, FITC conjugated anti-
humanBAFFreceptororAlexaFluor488-conjugatedanti-humanIL7-Rα.
Isotype controls were used to set positive and negative gates for BAFF-R,
IL-7-Rα, CD19 and CD10. Receptor antibodies as well as appropriate
isotype controls were purchased from BioLegend, San Diego, CA, USA.
A total of 20 000 CD19+ cells were acquired, and the proportion of
CD19+CD10+ and CD19+ CD10− cells expressing receptors and the
mean fluorescence intensity (MFC number) of staining (an indicator of
receptor density) were analysed using the CellQuest software.
Cytokine production by B cells
Human peripheral blood mononuclear cells were isolated, counted and
re-suspended to equal cell concentration. They were then incubated with
2 µg/mL of endotoxin-free un-methylated CpG oligodeoxynucleotides
(CpGODN2006,InvivoGen,SanDiego,CA,USA)for24h.Supernatants
were collected and stored at −70◦C until analysed. TNF-α,I L - 6a n dI L -
10 were measured by ELISA kits purchased from BD Pharmingen, San
Diego, CA, USA as per the manufacturer’s protocol.
Data analysis
QuadrantstatisticswereusedinthedotplotoftheCellQuestsoftware.The
relativeproportionandcalculatedabsolutenumbersofBlymphocytesand
their subsets were analysed with independent sample t-tests in SPSS. Data
were expressed as mean ± SEM, unless otherwise specified. P-values
< 0.05 were considered significant.
Results
General data
The data are summarized in Table 1. The underlying
cause of renal disease in the ESRD group included dia-
betic nephropathy in nine, hypertension in three, chronic
Table 2. Blood leukocyte counts given as mean ± SD in normal control
and ESRD groups
Control ESRD P-value
Total leukocytes 6100 ± 1300 7400 ± 1900 0.009
Neutrophils 3500 ± 900 4700 ± 1500 0.004
Monocytes 400 ± 100 500 ± 200 0.053
Lymphocytes 1900 ± 600 1500 ± 600 0.019
glomerulonephritis in seven and ESRD of unknown aetiol-
ogy in two patients. The types of vascular access included
A-V fistulas in 12, A-V grafts in 8 and tunnelled cen-
tral catheter in one of the patients. As expected, serum
creatinine, urea nitrogen, phosphorus and triglyceride con-
centrations were significantly higher in the ESRD patients
comparedtothecontrolgroup.Bloodhaemoglobinwassig-
nificantlylower,whereas,serumPTHandferritinlevelsand
transferrin saturation were higher, and serum albumin and
calcium concentrations were unchanged in the ESRD pa-
tients when compared with the corresponding values found
in the control group. The mean Kt/V value in the ESRD
patients was 1.62, reflecting adequacy of dialysis regimen
in the study participants.
Peripheral blood leukocyte data
The data are shown in Table 2. Compared to the normal
control group, the ESRD group exhibited a significant ele-
vationofthenumberoftotalwhitebloodcellsandpolymor-
phonuclear leukocytes and marked reduction of circulating
lymphocytes. No significant difference was found in the
numbers of circulating monocytes between the two groups.
B-lymphocyte subset data
Data are shown in Figures 1 and 2. The number of tran-
sitional B cells in the ESRD group was not significantly
different fromthat foundinthecontrol group. However, the
populations of innate B1 and conventional B2 cell subsets
were markedly reduced in the ESRD patients as compared
to the corresponding values in the normal control group.
Likewise, the numbers of na¨ ıve and memory B-cell sub-
sets were reduced in the ESRD group. Comparison of the
dataobtainedfromdiabeticandnon-diabeticESRDpatients
revealed no differences in either total B-lymphocyte count
or the B-cell subpopulations (Table 3).
No significant correlation was found between Kt/v and
eithertotalB-lymphocytecountoranyoftheB-cellsubsets.
Likewise,nosignificantcorrelationwasfoundbetweenFer-
ritin, which is a marker of inflammation, and iron stores
with either total B-lymphocyte count or the B-cell subsets.
However, a significant inverse correlation was found be-
tween the duration of dialysis treatment and the percentage
of CD19±/CD27± memory B cells (r =− 0.52, P = 0.04).
Apoptosis data
We next sought to determine whether increased apopto-
sis may account for the B-cell deficiency in ESRD pa-
tients. To this end, whole blood and isolated lymphocytes208 M. V . Pahl et al.
Fig. 1. Flow cytometric analysis of B-cell subsets. Whole blood was stained with anti-CD19 PerCP, anti-CD27 FITC, anti-CD5 PE or anti-CD10 PE.
CD19+ cells were gated for further analysis. B cells were divided into subpopulations according to the surface expression CD5+, CD27 and CD10;
CD5+ (innate B cells), CD5−(conventional B cells), CD27+ (memory B cells), CD27− (mature B cells) CD10+ (transitional B cells).
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Fig. 2. The absolute numbers of B cells in control (N = 21) and ESRD
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were stained with annexin V and anti-CD19 mAb (B-cell
marker). As demonstrated in Figure 3, no significant dif-
ferencewasfoundinspontaneousB-cellapoptosisbetween
theESRDpatientsandthenormalcontrolsubjects,thusex-
cluding heightened apoptosis as the main cause of B-cell
lymphopenia.
Plasma levels of interleukin-7 (IL-7) and BAFF
To further explore the potential mechanism(s) of B-cell
lymphopenia in ESRD patients, we measured plasma levels
of the main B-cell differentiation factor, IL-7 and B-cell
survival factor, BAFF, in the study populations. Surpris-
ingly, plasma IL-7 and BAFF levels were higher in ESRD
Table 3. Comparison of total B cells and B-cell subsets among diabetic
and non-diabetic ESRD patients
Diabetic Non-diabetic
(cells/µL) (cells/µL) P-value
Total B cells
(CD19+)
140 127 0.69
Memory B cells
(CD19+/CD27+)
36 25 0.37
Na¨ ıve B cells
(CD19+/CD27−)
104 102 0.93
Transitional B cells
(CD19+/CD10+)
27 27 0.98
Innate B1 cells
(CD19+/CD5+)
38 39 0.92
Conventional B2 cells
(CD19+/CD5−)
102 87 0.59
patients than those found in the control subjects (Figure 4).
It is of note that inflammation and lymphopenia are known
to promote production and release of BAFF [15–17]. The
observed elevation of BAFF in our ESRD patients may be
a consequence of lymphopenia and inflammation that are
common features of ESRD.
BAFF and IL-7 receptor data
To address the potential mechanism of B-cell lymphopenia
despite elevated IL-7 and BAFF levels, we next examined
expression of IL-7 and BAFF receptors on CD19+ CD10+
transitional B cells. Data are illustrated in Figure 5. The
study revealed a significant reduction of BAFF receptor
density on the transitional B cells from the ESRD groupEffect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression 209
Fig. 3. Flow cytometric analysis of B-cell apoptosis. Peripheral blood
lymphocytes were stained with anti-CD19 PerCP and Annexin V–PE.
CD19+ cells were gated and annexin+ cells were analysed.
as compared with that found in the controls. In addition,
the percentage of transitional B cells with detectable BAFF
receptor was mildly but significantly reduced in the ESRD
group. In contrast, the BAFF receptor density in the mature
Bcells(CD19+CD10−cells)andthepercentageofmature
B cells with detectable BAFF receptor were unchanged
in the ESRD patients when compared with those found
in controls. As expected IL-7 receptor expression was not
found in the circulating transitional B cells in either group.
This is not surprising since IL-7-responsive pre-B cells are
normally confined to the bone marrow.
The B-cell response to TLR9 activation
Results are shown in Figure 6. Previous in vitro studies
have shown that the production of IgM, IgA and IgG
is impaired in ESRD patients [11,18]. However, little is
known about the effect of ESRD on cytokine production
[19,20] that represents another function of B cells. Human
B cells express TLR9 [21,22] whose activation with un-
methylated DNA triggers the production of pro- and anti-
inflammatory cytokines. Activation of peripheral blood
lymphocytes with the TLR9 ligand, CpG ODN, resulted
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in significantly greater production of pro-inflammatory cy-
tokines, IL-6 and TNF alpha in the ESRD patients than
that in the control subjects. However, no significant differ-
ence was found in the production of the anti-inflammatory
cytokine, IL-10, between the ESRD and the control groups.
Discussion
The ESRD patients included in the present study exhib-
ited a marked reduction of all B-cell subpopulations except
transitional cells that were less severely affected. No differ-
ence was observed in the magnitude of B-cell deficiency
among diabetic and non-diabetic ESRD subgroups, point-
ing to the dominant role of ESRD in this process. These
findings point to the impact of uraemia on B-cell differen-
tiation and survival as a major cause of B-cell lymphopenia
and impaired humoral immunity in ESRD.
B lymphocytes are generated from haematopoietic stem
cellsinthebonemarrowthroughoutlife.Theycontributeto
the immune system by producing antigen-specific antibod-
ies. IL-7, is a pleiotropic cytokine that plays a major part
in B lymphopoiesis by promoting the maturation of pre-B
cells to B cells in the bone marrow [23,24]. After differen-
tiation and selection in the bone marrow, newly emerging B
lymphocytes (termed transitional B cells, CD19+ CD10+)
migrate to the spleen. In humans, CD10 is highly expressed
on B-cell progenitors in the bone marrow and progressively
disappears with maturation. A majority of CD10+ B cells
in the peripheral blood represent immature transitional B
cells [25,26]. Further differentiation of transitional B cells
into mature long-lived lymphocytes is critically dependent
on BAFF [27–29].
The diversity of the B-lymphocyte pool determines the
individual’s capacity to mount a protective immune re-
sponse. In adults, innate B1 cells (CD5+ B cells) account
for 25–27% of peripheral blood B lymphocytes. Innate B1
cells produce mainly IgM antibodies that have low-affinity
andhighcross-reactivityproperties[30,31].Theseantibod-
ies constitute a readily available pool of immunoglobulins
that fight a variety of infections prior to the production of
high-affinity-specific antibodies. On the other hand, con-
ventional B cells, otherwise known as B2 cells (CD5−
B cells), produce a more diverse array of antibodies with
high-affinity interactions, and account for 75–80% of pe-
ripheral blood B lymphocytes [31,32]. When the naive
mature B lymphocytes recognize antigen with their spe-
cific Ig receptors, they undergo clonal expansion and
differentiation into long-lived memory B cells (CD27+)
and plasma cells that produce and secrete antigen-specific
antibodies. Memory cells that can survive decades actively
circulate from blood to lymph nodes and populate mucosal
tissues. Upon a subsequent encounter with the antigen,
memory B cells respond rapidly by producing Ig isotypes
with a high affinity for the given antigen. In adult humans,
∼40%ofallcirculatingBcellsarememoryBcells[33,34].
B-cell lymphopenia has been previously reported in
ESRD patients [18,35–41]. In addition, a diminished pop-
ulation of CD5+ innate B cells and CD27+ memory
B cells has been demonstrated in children with chronic
renal failure [35]. The present study extends those findings
by demonstrating that ESRD causes depletion of several
other B-cell subtypes in adults and by showing that B-cell
lymphopenia is unlikely a consequence of either increased
peripheral apoptosis or deficiencies in IL-7 or BAFF, two
key B-cell differentiation and survival factors.
In this study, we found that transitional B cells were not
significantly reduced in ESRD patients suggesting that de-
creased output of B cells from bone marrow may not be the
main cause of the B-cell lymphopenia in ESRD patients.
This view is supported by the finding that plasma levels of
IL-7, a cytokine that facilitates conversion of pre-B cells to
B cells, were increased in ESRD patients. Two alternative
mechanismscanbeproposedtoaccountforBlymphopenia
in ESRD. First, the uraemic milieu may increase suscepti-
bility of B cells to apoptosis in ESRD patients. Second, the
uraemic environment may render transitional B cells resis-
tant to differentiation and survival signals. The above two
possibilities are not mutually exclusive.
In the present study, we found no difference in the pro-
portions of apoptotic B cells among the ESRD patients and
control subjects. In contrast, Fern´ andez-Fresnedo et al.r e -
portedincreasedapoptosisofBcellsobtainedfrompatients
with chronic renal failure [39]. The cause of this discrep-
ancymayberelatedtothetechniquesusedtodetectapopto-
sis. Fern´ andez-Fresnedo et al. cultured the peripheral blood
cells for 96 h prior to assessing apoptosis, whereas we as-
sessedapoptosisonfreshlyisolatedcells.Itshouldbenoted
that the inability to detect increased apoptosis in freshly
isolated cells could be due to loss of apoptotic cells dur-
ing the cell isolation procedure. This is unlikely, however,
since we found no increase in the apoptotic B cells with
the whole blood staining technique. However, we cannot
exclude the possibility that increased apoptosis of B cells
might have occurred in other compartments of the immune
system.
The growth and differentiation of B cells from stem cell
tomatureplasmacellaregoverned,amongotherfactors,by
the level of cytokines in the microenvironment and the ex-
pression of their respective receptors on the cells. The pres-
ence of severe B lymphocytopenia in the face of elevation
of IL-7 and BAFF that are the major B-cell differentiation
and survival factors is indicative of uraemia-induced B cell
resistance to the action of these cytokines. Since biological
actions of IL-7 and BAFF depend on activation of their
receptors and down-stream signal transduction pathways,Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression 211
we next examined expression of IL-7 and BAFF recep-
tors on transitional (CD19+ CD10+) and mature (CD19+
CD10−) B cells to determine whether B-cell lymphope-
nia in ESRD may be a consequence of a defect in B-cell
differentiation from transitional cells to mature B cells or
decreased survival of mature B cells. BAFF binds with
similarly high affinity to three receptors: BCMA (B-cell
maturation antigen), TACI (transmembrane activator and
CAML-interactor) and BAFF receptor [16]. Since studies
in BCMA, TACI and BAFF receptor-deficient mice indi-
cated that the BAFF differentiation and survival signal in
transitional and mature B cells are mediated by the BAFF-
receptor and not through BCMA and TACI [16], we ex-
amined the expression of BAFF receptor on transitional
and mature B cells. We found a significant reduction of
BAFF receptor density on transitional B cells and not on
mature Bcells fromthe ESRD group as compared withthat
found in the controls. In addition, the percentage of tran-
sitional B cells with detectable BAFF receptor was mildly
but significantly reduced in the ESRD group. These results
would suggest that uraemia impacts the differentiation of
transitional B cells rather than the survival of mature B
cells. Furthermore, the elevation of the circulating BAFF
levels and the normality of BAFF receptor expression in
mature B cells preclude the deficiency of either as the pri-
mary cause of the observed reduction of mature circulating
B cells (CD19+ CD10−) in ESRD. Down-regulation of
BAFF receptor expression on transitional B cells can con-
stitute resistance to the biological actions of BAFF and as
such may, in part, contribute to the pathogenesis of B-cell
lymphopenia in ESRD patients. It should be noted that the
observed down-regulation of the BAFF receptor in transi-
tional B cells from ESRD patients may be a response of
these cells to the elevated BAFF concentrations.
Further studies are needed to explore the effects of
uraemia on B-cell precursors in the bone-marrow and
down-stream signal transduction pathways involved in B-
cell growth, differentiation and survival. Regardless of the
cause, uraemia-induced na¨ ıve and memory B-cell lym-
phopenia is, in part, responsible for the defective humoral
response to infections, vaccination and recall antigens and
increased incidence of infection in ESRD patients.
Earlier studies have shown that B-cell antibody produc-
tion capacity is impaired in ESRD patients [11,18]. In ad-
dition to their well-known function as antibody-producing
cells, B cells significantly contribute to the production of
pro- and anti-inflammatory cytokines such as TNF-α,I L - 6
and IL-10 [19,20]. In this study, we sought to examine the
effect of ESRD on the cytokine-producing capacity of B
cells. The study revealed that stimulation of lymphocytes
with the TLR9 agonist elicited significantly greater IL-6
and TNF production in the ESRD group as compared to the
controlgroup.ItshouldbementionedthatinhumansTLR9
is primarily expressed by B cells, but is also expressed by
plasmacytoid dendritic cells [21,22]. Given the small size
of the plasmacytoid dendritic cell population (∼0.06% of
circulating leukocytes) and relatively large population of B
cells(8–11%),theobservedincreaseincytokineproduction
in response to the TLR9 activation must be largely derived
from the B-cell population. The mechanism(s) responsi-
ble for heightened production of inflammatory cytokines
by uraemic B cells in response to the TLR9 agonist is not
known. However, it reflects the participation of B cells in
the prevailing inflammatory milieu in uraemia.
The present study did not include as yet un-dialysed
ESRD patients or ESRD patients maintained on peritoneal
dialysis, the available data do not allow conclusions as to
the potential contribution of dialysis modalities to the ob-
served B-cell lymphopenia. However, earlier studies [13]
have found an equal reduction of total B cells (CD19±)
in as yet un-dialysed ESRD patients and those maintained
on either haemodialysis or peritoneal dialysis modalities.
These observations tend to illustrate the dominant role of
ESRD as opposed to the dialysis modalities in the patho-
genesis of the associated B-cell lymphopenia.
In conclusion, despite elevation of B-cell growth/
differentiation factors, ESRD patients exhibited diffuse re-
duction of B-cell subpopulations. This was associated with
down-regulation of the BAFF receptor in transitional B
cells. The latter can, in part, contribute to B-cell lymphope-
nia by promoting resistance to the biological actions of
BAFF that is a potent B-cell survival factor. Despite their
reduced numbers, the uraemic B cells had a heightened ca-
pacity to produce inflammatory cytokines suggesting their
possibleparticipationintheprevailinginflammatorymilieu
in uraemia.
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Abstract
Background. The accumulation of larger and protein-
bound toxins is involved in the uraemic syndrome but their
elimination by dialysis therapy remains difficult. In the
present study, the impact of the albumin permeability of re-
cently introduced advanced high-flux dialysis membranes
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